MedTrace Logo

Acceptability and Feasibility of Medical Abortion Using Mifepristone and Buccal Misoprostol

NCT00386282 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1250

Last updated 2014-07-30

No results posted yet for this study

Summary

This study examined the acceptability and feasibility of introducing a mifepristone-misoprostol regimen of medical abortion into abortion services in two private clinics in Puerto Rico; 2 clinics in Baku, Azerbaijan; 3 clinics in Yerevan, Armenia; and 4 clinics in Mexico City. It was hypothesized that the study regimen would be both acceptable and efficacious.

Conditions

  • Abortion, First Trimester

Interventions

DRUG

mifepristone-misoprostol treatment

200 mg mifepristone followed by 800 mcg buccal misoprostol 24-48 hours after the mifepristone.

Sponsors & Collaborators

  • Gynuity Health Projects

    lead OTHER

Principal Investigators

  • Hector Diaz Martinez, MD · Clinica de Planificacion Familiar

  • Angela Arredondo, MD · Woman's Metropolitan Center

  • Beverly Winikoff, MD, MPH · Gynuity Health Projects

  • Gulnara Rzaeva, MD · Scientific Research Institute of Obstetrics & Gynecology

  • Besti Muradova, MD · Family Planning Center

  • Susanna Fildjyan, MD · Institute of Perinatology, Obstetrics and Gynecology

  • Armine Harutyunyan, MD · Center for Family Planning and Sexual Health

  • Anna Aghajanyan, MD · State Medical University

  • Ranulfo Rios, MD · H G Enrique Cabrera

  • Laura Garcia Martinez, MD · H.M.I Inguaran

  • Antonio E Flores, MD · C S Beatriz Velasco Aleman

  • Elba Margarita Lugo Hernandez, MD · C S Santa Catarina

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2011-03-31
Completion
2011-03-31

Countries

  • Armenia
  • Azerbaijan
  • Mexico
  • Puerto Rico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00386282 on ClinicalTrials.gov